摘要
高钾血症是慢性肾脏病常见的并发症,其发生常与肾小球滤过率的下降、肾素-血管紧张素-醛固酮系统抑制剂的应用,尤其是药物的联合应用以及代谢性酸中毒有关。治疗高钾血症的口服药物中最常应用的是阳离子交换树脂,其传统药物为聚苯乙烯磺酸盐,但其有效性和安全性至今仍存在争议。近年来出现了新型药物如patiromer和环硅酸锆钠,其降钾效果和安全性均优于传统药物,成为高钾血症的有效治疗药物。
Hyperkalemia is a common complication of chronic kidney disease,and its occurrence is often related to the decline of glomerular filtration rate,the application of renin-angiotensin-aldosterone system inhibitors,and especially combined application of the drugs as well as metabolic acidosis.The most commonly used oral drug for the treatment of hyperkalemia is cation exchange resin,whose traditional drug is polystyrene sulfonate,but its effectiveness and safety are still controversial.In recent years,new drugs such as patiromer and sodium zirconium cyclosilicate have been developed,and their potassium-lowering effect and safety are better than the traditional drugs,having become the effective drugs for the treatment of hyperkalemia.
作者
毕靖茹
王艺璇
周广宇
吴晨
郭硕杰
郑盼盼
Bi Jingru;Wang Yixuan;Zhou Guangyu;Wu Chen;Guo Shuojie;Zheng Panpan(Department of Nephrology,China-Japan Union Hospital of Jilin University,Changchun 130033,Jilin Province;First People′s Hospital of Xuzhou City,Xuzhou 221100,Jiangsu Province,China)
出处
《中华肾病研究电子杂志》
2021年第3期162-165,共4页
Chinese Journal of Kidney Disease Investigation（Electronic Edition）
基金
吉林省科技厅自然基金项目(20200201437JC)。
